Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Coral Laboratories Ltd

Your Vote -

Buy

40.00%

Hold

20.00%

Sell

40.00%

40.00%

5 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Coral Laboratories Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Coral Labs. Q3 net profit zooms 184.26% at Rs 6.14 cr

    13 Feb 2025, 8:30PM The company reported standalone net profit of Rs 6.14 crore for the quarter ended December 31, 2024 as compared to Rs 2.16 crore in the same period la
  • Coral Labs. - Integrated Filing (Financial)

    13 Feb 2025, 8:08PM In accordance with amendments to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Third Amendment) Regulations, 2024 read
  • Coral Labs. - To Consider And Adopt The Unaudited Standalone Financial Results For The Quarter And Nine Months Ended December

    13 Feb 2025, 6:56PM To consider and adopt the Unaudited Standalone Financial Results for the quarter and nine months ended December 31 2024, with the Limited Review Repor
  • Coral Labs. - Board Meeting Outcome for Outcome Of The Board Meeting Held On February 13, 2025, Pursuant To Regulation 30 (Re

    13 Feb 2025, 6:49PM To consider and adopt the Unaudited Standalone Financial Results for the quarter and nine months ended December 31 2024, with the Limited Review Repor
  • Coral Labs. - Board Meeting Intimation for Considering, Approving And Taking On Record The Unaudited Financial Results Of The

    5 Feb 2025, 5:27PM CORAL LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 ,inter alia, to consider
  • Coral Labs. has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024

    17 Jan 2025, 5:40PM As of December 2024, 71.51% is owned by Promoters and 28.49% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 19.97% and F
  • Coral Labs. - Change Of Name Of Registrar And Share Transfer Agent Of The Company

    3 Jan 2025, 12:33PM Change Of Name Of Registrar And Share Transfer Agent Of The Company
  • Coral Labs. - Notice For Non-Compliance With SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    19 Dec 2024, 5:32PM Dear Sir/ Madam,\r\n\r\nPursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015\r\n('SEBI (LODR) Regulat

Key fundamentals

Evaluate the intrinsic value of Coral Laboratories Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 177.4966 154.7981 162.0922 142.8974 121.5833
Liabilities 177.4966 154.7981 162.0922 142.8974 121.5833
Equity 3.5726 3.5726 3.5726 3.5726 3.5726
Gross Profit 16.2389 3.8117 8.2142 15.8492 5.2903
Net Profit 15.789 6.4454 9.0457 13.5546 7.1303
Cash From Operating Activities -5.4646 12.6652 6.0837 1.1169 -3.8629
NPM(%) 18.87 8.25 11.96 14.03 10.1
Revenue 83.6605 78.1185 75.6107 96.5673 70.5795
Expenses 67.4216 74.3068 67.3965 80.7181 65.2892
ROE(%) 7.75 3.16 4.44 6.65 3.5

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Coral Laboratories Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 809.25 -0.64 11.41 432.38 1321.50 1.42
Lotus Eye Hospital and Institute Ltd 58.19 1.50 237.75 1575.53 14.01 0.88
Bharat Immunological and Biologicals Corporation Ltd 21.32 -1.30 0.00 3271.32 -39.50 0.00
Astec Lifesciences Ltd 654.90 -5.39 0.00 1485.59 -239.30 0.00

Company Info

Coral Laboratories P Ltd was incorporated on 19.6.1981 and was then converted into a Public Ltd company vide special resolution passed by the shareholders at the meeting held on 9th March 93. The company proposes to manufacture various pharmaceuticals formulations like tablets, capsules, dry syrups, liquieds and ointments and the company has not undertaken any commercial or business activity till date. The company has been promoted by Mr. N B Doshi, Chairman & Managing Director of the company. 2000 - Received WHO GMP Certificate for Baroda Plant. - Received ISO 9002 Certificate of Quality System Assessment issued by American Quality Assessors. 2001 - Entered in Global Marketing and started Exporting to Sri Lanka, Papua New Guinea, Cambodia and Kenya. - Renewal of WHO - GMP Certificate. 2002 - Entered into New Global Markets such as Ghana, Malawi, Nigeria, Lesotho, Ukraine and Vietnam. 2003 - Manufacturing Unit approved by (NAFDAC) Nigeria Food & Drug Administration. 2004 - Daman manufacturing unit started manufacturing since March 2004. This manufacturing unit is design to acquirer U.S. FDA & U.K. MHRA Certification. - Established a Quality Management System that is in compliance with the International Quality System Standard ISO 9001: 2008 Certificate Certificate No: IN015692. 2005 - Received WHO - GMP Certificate for Daman Plant. Manufacturing Unit No. 3 under construction at Dehradun. - Started Contract Manufacturing for ACI Pharm - USA and Medicale Pharmaceutique- France for their exports. - Recd ISO 9001-2008 Certificate for Daman plant. 2006 - Started Dehra Doon plant having facility to manufacture Tablets, Capsules, Liquids, Ointments, Lotion, Dry Syrup, Injectables(Dry Powder). 2009 - Received WHO GMP Certificate for Dehradun Plant. 2011 -Coral Laboratories Ltd has recommended dividend @ 15% i.e. Rs. 1.50 per Equity Shares of Rs. 10/-. 2012 -Coral Laboratories Ltd has recommended Dividend @ 15 % i.e. Rs. 1.50/-. per equity share of Rs. 10/- each. 2013 -Coral Laboratories Ltd has recommended Final Dividend @ 15 % i.e. Rs. 1.50/- per equity share of Rs. 10/- each 2014 -Coral Laboratories Ltd has recommended Dividend @ 20% i.e. Rs. 2/- per equity share of Rs. 10/- each.

Coral Laboratories P Ltd was incorporated on 19.6.1981 and was then converted into a Public Ltd company vide special resolution passed by the shareholders at the meeting held on 9th March 93. The company proposes to manufacture various pharmaceuticals formulations like tablets, capsules, dry syrups, liquieds and ointments and the company has not undertaken any commercial or business activity till date. The company has been promoted by Mr. N B Doshi, Chairman & Managing Director of the company. 2000 - Received WHO GMP Certificate for Baroda Plant. - Received ISO 9002 Certificate of Quality System Assessment issued by American Quality Assessors. 2001 - Entered in Global Marketing and started Exporting to Sri Lanka, Papua New Guinea, Cambodia and Kenya. - Renewal of WHO - GMP Certificate. 2002 - Entered into New Global Markets such as Ghana, Malawi, Nigeria, Lesotho, Ukraine and Vietnam. 2003 - Manufacturing Unit approved by (NAFDAC) Nigeria Food & Drug Administration. 2004 - Daman manufacturing unit started manufacturing since March 2004. This manufacturing unit is design to acquirer U.S. FDA & U.K. MHRA Certification. - Established a Quality Management System that is in compliance with the International Quality System Standard ISO 9001: 2008 Certificate Certificate No: IN015692. 2005 - Received WHO - GMP Certificate for Daman Plant. Manufacturing Unit No. 3 under construction at Dehradun. - Started Contract Manufacturing for ACI Pharm - USA and Medicale Pharmaceutique- France for their exports. - Recd ISO 9001-2008 Certificate for Daman plant. 2006 - Started Dehra Doon plant having facility to manufacture Tablets, Capsules, Liquids, Ointments, Lotion, Dry Syrup, Injectables(Dry Powder). 2009 - Received WHO GMP Certificate for Dehradun Plant. 2011 -Coral Laboratories Ltd has recommended dividend @ 15% i.e. Rs. 1.50 per Equity Shares of Rs. 10/-. 2012 -Coral Laboratories Ltd has recommended Dividend @ 15 % i.e. Rs. 1.50/-. per equity share of Rs. 10/- each. 2013 -Coral Laboratories Ltd has recommended Final Dividend @ 15 % i.e. Rs. 1.50/- per equity share of Rs. 10/- each 2014 -Coral Laboratories Ltd has recommended Dividend @ 20% i.e. Rs. 2/- per equity share of Rs. 10/- each.

Read More

Parent Organisation

Coral Laboratories Ltd.

Founded

06/02/1997

Managing Director

NSE Symbol

FAQ

The current price of Coral Laboratories Ltd is

The 52-week high for Coral Laboratories Ltd is

The market capitalization of Coral Laboratories Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Coral Laboratories Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Coral Laboratories Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Coral Laboratories Ltd shares.

The CEO of Coral Laboratories Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT